Beyond Border 2006 is Ernst & Young's 20th anniversary edition of its leading industry reports. The modern biotechnology sector turns 30 this year. It began with the foundation of Genentech in April 1976, 30 years ago. The biotechnology sector is booming across the planet from US to Asia Pacific. It reached its all time high of US$63.1 billion, and accumulated US$19.7 billion in capital.
Ernst & Young has been tracking the progress of biotechnology for the last two decades. Beyond Borders: Global Biotechnology Report 2006 is Ernst & Young Global Biotechnology Center's 20th anniversary annual report. The report includes comprehensive data, in-depth analysis, market insights, and key trends for the biotechnology sector. They have special time line charting on the long term evolution of the industry. According to the report, the biotechnology industry has endured all obstacles and has thrived. Even the market valuations of biotechnology's most successful companies are posing as a challenge to the big pharmacy.
The global biotechnology industry is making remarkable growth in almost every performance area. It has achieved double digit growth and is becoming more and more profitable. In America, for the third consecutive year, the biotechnology sector delivered strong product approvals and concrete financial results. In Europe, it has achieved record breaking venture capital. They saw thriving IPO's, flourishing M&As and coalitions. As far as the growth pace of biotechnology is concerned, credit goes to Asia Pacific for its rapid 46% revenue growth and significant progress towards productivity.
America got 32 new products approved in the year 2005 that include 17 first time approval. In Europe a total of ?3.2 billion (US$4 billion) in capital was made. The publicity traded biotech companies increased by 28% in Europe. In Asia Pacific, the government emphasis on biotech as a tactical precedence is aiding the biotechnology sector to bloom. Beyond Borders 2006 provides a strategic outlook of biotechnology at global level. It provides insight into key provincial markets including America, Asia Pacific, and Europe. Taking a tour of the report from Ernst and Young Global biotechnology center reveals the whole network of research and analysis that are carried out actively by the Big Four firms to anticipate what is in store for the upcoming years.
